Novo Nordisk Unveils Bold 2030 Strategy Amid Competitive Pressure and Investor Concerns

September 21, 2026
Novo Nordisk Unveils Bold 2030 Strategy Amid Competitive Pressure and Investor Concerns
  • In a Capital Markets Day focused on growth, Novo Nordisk outlined a plan to launch more than five multi-blockbuster drugs annually by 2030, with a goal of over 150 billion Danish kroner in pipeline sales by 2035, driven by an expanded metabolic drug pipeline spanning obesity, diabetes, and other areas.

  • The company intends at least five Phase 3 trials in obesity and diabetes, plus an additional five Phase 3 studies in other therapeutic areas, as part of a broader diversification strategy.

  • Management signaled a strategic pivot to sustain growth by expanding the pipeline, aiming to restore growth and diversify beyond semaglutide-focused revenue.

  • Shares initially fell as much as about 7–8% in response to the announcements at the London Capital Markets Day.

  • Analysts noted a discrepancy between reported growth and adjusted figures, highlighting pricing pressure and mix as core concerns in the near term.

  • Investor focus shifted to questions about pricing power and future dealmaking ahead of Wegovy and Ozempic patent expiries, contributing to a stock pullback of up to around 9%.

  • Although positive news emerged from Phase 3 topline data for CagriSema, investors remained wary about long-term market share erosion and near-term commercialization hurdles.

  • Overall analyst sentiment cooled, with downgrades and valuation re-ratings reflecting muted medium-term growth prospects and pipeline lag.

  • The briefing took place during Capital Markets Day in London, underscoring a deliberate shift to sustain growth in a crowded competitive landscape.

  • A US regulatory decision for Cagri-Sema is anticipated in the fourth quarter, a potential catalyst for the obesity/multi-blockbuster strategy.

  • Novo’s GLP-1 franchise remains a smaller revenue contributor than Eli Lilly’s, which holds a roughly 2-to-1 sales advantage and stronger recent performance in obesity and diabetes therapies.

  • In Q2, Novo controlled about 39% of the obesity drug market while Eli Lilly held about 61%, signaling continued competitive pressure on Novo’s weight-management portfolio.

Summary based on 15 sources


Get a daily email with more EU News stories

More Stories